Cellectar Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
59.3%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$2.43next fiscal year
Monitoring Framework
Key Performance Indicators
Major Response Rate (MRR) in r/r Waldenström Macroglobulinemia (WM) Quarterly6,180.0%Target: Exceed the FDA-agreed statistical hurdle of 20%
Overall Response Rate (ORR) in r/r Waldenström Macroglobulinemia (WM) Quarterly8,360.0%Target: Maximize clinical benefit in heavily pretreated populations
Median Duration of Response (DoR) in r/r Waldenström Macroglobulinemia (WM) Quarterly1,780.0%Target: Demonstrate long-term durability of response
Cash and Cash Equivalents Quarterly8.3MTarget: Maintain sufficient runway to fund operations into Q2 2027
Watch Items
- EMA Conditional Marketing Authorization (CMA) Submission for iopofosine I 131 in WMTrigger: Submission planned for 3Q 2026Action: Monitor regulatory filing progress and feedback from the European Medicines Agency
- U.S. FDA Accelerated Approval NDA Preparation for iopofosine I 131 in WMTrigger: Ongoing preparation following mature 12-month follow-up dataAction: Track timeline for NDA submission and FDA acceptance of the filing
- Initiation of Phase 3 Confirmatory Trial for iopofosine I 131 in WMTrigger: Planned initiation in late Q4 2026Action: Verify trial design approval, site activation, and first patient dosing
- CLR 125 Phase 1b Trial in Triple-Negative Breast Cancer (TNBC)Trigger: Interim data readout expected mid-2026Action: Evaluate safety, dosimetry, and early efficacy signals from the Auger-emitting program
Research as of 20 Jun 2026